Aspira Women’s Health Inc. (NASDAQ:AWH) Short Interest Up 10.9% in January

Aspira Women’s Health Inc. (NASDAQ:AWH) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 439,200 shares, a growth of 10.9% from the January 15th total of 396,200 shares. Approximately 3.6% of the company’s shares are short sold. Based on an average trading volume of 97,900 shares, the short-interest ratio is presently 4.5 days.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on Aspira Women’s Health in a research note on Sunday, January 12th. They set a “hold” rating on the stock.

Aspira Women’s Health Trading Down 14.3 %

Shares of Aspira Women’s Health stock opened at $0.24 on Monday. Aspira Women’s Health has a 12-month low of $0.20 and a 12-month high of $5.00. The firm’s 50 day simple moving average is $0.57 and its two-hundred day simple moving average is $0.79. The firm has a market capitalization of $4.00 million, a price-to-earnings ratio of -0.20 and a beta of 1.38.

Institutional Investors Weigh In On Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. boosted its holdings in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 33.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 316,294 shares of the company’s stock after purchasing an additional 79,898 shares during the period. B. Riley Wealth Advisors Inc. owned about 1.90% of Aspira Women’s Health worth $256,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 12.19% of the stock is owned by hedge funds and other institutional investors.

Aspira Women’s Health Company Profile

Aspira Women’s Health, Inc engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.